← back to search

Eduardo Díaz‐Rubio

Instituto de Investigación Sanitaria del Hospital Clínico San Carlos · ES
Area of research
Oncology · Pathology and Forensic Medicine
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Cancer Treatment and Pharmacology, Genetic factors in colorectal cancer, and Cancer Genomics and Diagnostics.
h-index
65
citations
22,907
works
540
NIH funding
primary concept
email

Recent publications

La gran oportunidad: La detección de la enfermedad mínima residual (EMR) en el cáncer colorrectal localizado mediante ADN tumoral circulante (ADNtc)
ANALES RANM 2026cited by 0position: contributordoi
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis
European Journal of Cancer 2024cited by 19position: middledoi
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials
European Journal of Cancer 2023cited by 11position: middledoi
Molecular Classification of Colorectal Cancer by microRNA Profiling: Correlation with the Consensus Molecular Subtypes (CMS) and Validation of miR-30b Targets.
2022cited by 8position: contributordoi
Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer
JNCI Journal of the National Cancer Institute 2021cited by 28position: middledoi
Quantitative Thermal Imaging Biomarkers to Detect Acute Skin Toxicity From Breast Radiation Therapy Using Supervised Machine Learning
International Journal of Radiation Oncology*Biology*Physics 2020cited by 40position: middledoi
Thermoradiomic Markers of Radiation-Induced Skin Toxicity: Updated Results of a Phase II Study
Journal of medical imaging and radiation sciences 2020cited by 0position: middledoi
Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts.
2019cited by 8position: contributordoi
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
Critical Reviews in Oncology/Hematology 2018cited by 267position: middledoi
Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database
European Journal of Cancer 2018cited by 76position: middledoi
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group
European Journal of Cancer 2018cited by 34position: middledoi
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project
JNCI Journal of the National Cancer Institute 2017cited by 143position: middledoi
Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database
Journal of Clinical Oncology 2017cited by 47position: middledoi
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Annals of Oncology 2016cited by 3,428position: middledoi
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
The Lancet Oncology 2016cited by 650position: middledoi
Abstract P2-08-08: Circulating tumor cells count-based nomograms to predict survival of metastatic breast cancer patients: Results from the European pooled analysis
Cancer Research 2016cited by 0position: middledoi
Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database
Journal of Clinical Oncology 2015cited by 180position: middledoi
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
The Lancet Oncology 2014cited by 835position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Alfredo Falcone · Azienda ospedaliera "Bianchi-Melacrino-Morelli"3 papers (2015–2018)Daniel J. Sargent · National Institute of Agricultural Botany3 papers (2015–2018)Volker Heinemann · LMU Klinikum3 papers (2015–2018)Cornelis J.A. Punt · Oklahoma State University Center for Health Sciences3 papers (2015–2018)Aimery de Gramont · Institut Hospitalier Franco Britannique3 papers (2015–2018) · 3 papers (2019–2026)Benoist Chibaudel · Pôle de Recherche pour l'Organisation et la Diffusion de l'Information Géographique2 papers (2015–2016)Sami Tabbarah · Sunnybrook Health Science Centre2 papers (2020–2020)Ali Sadeghi‐Naini · Sunnybrook Health Science Centre2 papers (2020–2020)Richard Adams · Northeast Georgia Medical Center2 papers (2015–2016) · 2 papers (2020–2020)Christophe Tournigand · Inserm2 papers (2015–2016)Leonard B. Saltz · Cornell University2 papers (2015–2016)William T. Tran · York University2 papers (2020–2020)Edward Chow · Sunnybrook Health Science Centre2 papers (2020–2020)Tina Wu · Anhui Medical University2 papers (2020–2020)Michel Seymour · University of Leeds2 papers (2015–2016)Miriam Koopman · Dutch Colorectal Cancer Group2 papers (2016–2018)Enrique Aranda · Roche (Spain)2 papers (2018–2023)Khadijeh Saednia · York University2 papers (2020–2020)